[go: up one dir, main page]

PL1871341T3 - Naładowane kompleksy lipoproteinowe i ich zastosowanie - Google Patents

Naładowane kompleksy lipoproteinowe i ich zastosowanie

Info

Publication number
PL1871341T3
PL1871341T3 PL06727346T PL06727346T PL1871341T3 PL 1871341 T3 PL1871341 T3 PL 1871341T3 PL 06727346 T PL06727346 T PL 06727346T PL 06727346 T PL06727346 T PL 06727346T PL 1871341 T3 PL1871341 T3 PL 1871341T3
Authority
PL
Poland
Prior art keywords
lipoprotein complexes
charged lipoprotein
complexes
charged
impart
Prior art date
Application number
PL06727346T
Other languages
English (en)
Inventor
Jean-Louis H Dasseux
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36659702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1871341(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of PL1871341T3 publication Critical patent/PL1871341T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
PL06727346T 2005-03-24 2006-03-23 Naładowane kompleksy lipoproteinowe i ich zastosowanie PL1871341T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66518005P 2005-03-24 2005-03-24
EP06727346A EP1871341B8 (en) 2005-03-24 2006-03-23 Charged lipoprotein complexes and their uses
PCT/IB2006/000635 WO2006100567A1 (en) 2005-03-24 2006-03-23 Charged lipoprotein complexes and their uses

Publications (1)

Publication Number Publication Date
PL1871341T3 true PL1871341T3 (pl) 2012-07-31

Family

ID=36659702

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06727346T PL1871341T3 (pl) 2005-03-24 2006-03-23 Naładowane kompleksy lipoproteinowe i ich zastosowanie
PL10010660T PL2289490T3 (pl) 2005-03-24 2006-03-23 Naładowane kompleksy lipoproteinowe i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10010660T PL2289490T3 (pl) 2005-03-24 2006-03-23 Naładowane kompleksy lipoproteinowe i ich zastosowanie

Country Status (19)

Country Link
US (4) US8206750B2 (pl)
EP (3) EP2327396A3 (pl)
JP (2) JP5317691B2 (pl)
KR (4) KR101769191B1 (pl)
CN (2) CN103182069B (pl)
AT (1) ATE547094T1 (pl)
AU (1) AU2006226045B2 (pl)
BR (1) BRPI0607728A2 (pl)
CA (1) CA2602024C (pl)
CY (2) CY1112783T1 (pl)
DK (2) DK2289490T3 (pl)
ES (2) ES2509216T3 (pl)
IL (3) IL186169A (pl)
MX (1) MX2007011851A (pl)
NZ (2) NZ562346A (pl)
PL (2) PL1871341T3 (pl)
PT (2) PT1871341E (pl)
SI (2) SI2289490T1 (pl)
WO (1) WO2006100567A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
DK2396017T3 (en) * 2009-02-16 2015-09-14 Cerenis Therapeutics Holding Sa Apolipoprotein A-I-mimetika
EP2453876A1 (en) 2009-07-16 2012-05-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
US20130197226A1 (en) * 2010-07-28 2013-08-01 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
EP2611418A2 (en) * 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-1, lipid particles containing it and its use
HUE042314T2 (hu) * 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
AU2015271986B2 (en) * 2011-02-07 2018-02-22 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof
WO2012135046A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
WO2014160237A2 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosing preeclampsia
CN105051051B (zh) 2013-03-15 2021-07-16 萨瑞斯治疗控股公司 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US20170165200A1 (en) * 2015-11-20 2017-06-15 University Of North Texas Health Science Center Composition of lipid-based nanoparticles for small molecules and macromolecules
WO2019030574A1 (en) * 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
TW201919686A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
CN110151972A (zh) * 2018-02-11 2019-08-23 中国中医科学院中医基础理论研究所 基于多肽的重组高密度脂蛋白前体及其制备方法与应用
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
CN115666720A (zh) 2020-04-16 2023-01-31 阿比奥尼克斯制药公司 用于治疗肾病的cer-001疗法
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
KR102531293B1 (ko) * 2021-12-06 2023-05-16 (주) 멥스젠 신규한 재구축 고밀도 지단백 나노입자
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052123A (pl) * 1973-01-18 1975-05-09
US4466958A (en) 1981-03-18 1984-08-21 Morrison L M Food supplement
JPS59164553A (ja) * 1983-03-08 1984-09-17 Fuji Photo Film Co Ltd カラ−写真感光材料
DE3417696A1 (de) * 1984-05-12 1985-11-14 Robert Bosch Gmbh, 7000 Stuttgart Vorrichtung zum volumetrischen abmessen und abfuellen von fluessigkeitsmengen
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5231090A (en) 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5948756A (en) 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
JP2004505035A (ja) 2000-07-31 2004-02-19 オタワ・ハート・インスティテュート・リサーチ・コーポレーション 荷電脂質組成物及びその使用方法
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
FR2836043B1 (fr) 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
BR0310099A (pt) 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
PL374126A1 (pl) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Sposoby i kompozycje do leczenia reperfuzji niedokrwiennej
WO2004010939A2 (en) 2002-07-30 2004-02-05 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai

Also Published As

Publication number Publication date
PT2289490E (pt) 2014-10-13
US11801282B2 (en) 2023-10-31
US20120245328A1 (en) 2012-09-27
US20170182121A1 (en) 2017-06-29
US8617615B2 (en) 2013-12-31
IL186169A (en) 2012-06-28
IL219721A (en) 2016-04-21
BRPI0607728A2 (pt) 2009-10-06
ES2382958T3 (es) 2012-06-14
CA2602024A1 (en) 2006-09-28
ATE547094T1 (de) 2012-03-15
IL186169A0 (en) 2008-01-20
ES2509216T3 (es) 2014-10-17
PT1871341E (pt) 2012-06-01
US20140206600A1 (en) 2014-07-24
WO2006100567A1 (en) 2006-09-28
CN101170994B (zh) 2013-01-02
KR20140088616A (ko) 2014-07-10
IL186245A0 (en) 2008-01-20
IL219721A0 (en) 2012-06-28
HK1156840A1 (en) 2012-06-22
DK1871341T3 (da) 2012-06-18
CY1112783T1 (el) 2016-02-10
CN103182069B (zh) 2016-09-07
SI1871341T1 (sl) 2012-06-29
NZ562346A (en) 2010-03-26
EP1871341A1 (en) 2008-01-02
EP2289490B1 (en) 2014-07-23
JP5542166B2 (ja) 2014-07-09
AU2006226045B2 (en) 2012-01-19
KR101769191B1 (ko) 2017-08-30
JP5317691B2 (ja) 2013-10-16
US9567388B2 (en) 2017-02-14
CN103182069A (zh) 2013-07-03
NZ582888A (en) 2012-04-27
JP2012121928A (ja) 2012-06-28
KR20160077225A (ko) 2016-07-01
EP2289490A1 (en) 2011-03-02
EP2327396A3 (en) 2012-01-18
EP1871341B8 (en) 2012-04-11
CA2602024C (en) 2014-10-14
KR20080002861A (ko) 2008-01-04
KR20180026548A (ko) 2018-03-12
JP2008534487A (ja) 2008-08-28
KR101475419B1 (ko) 2014-12-22
CY1115613T1 (el) 2017-01-04
PL2289490T3 (pl) 2015-02-27
MX2007011851A (es) 2008-02-22
DK2289490T3 (da) 2014-10-13
HK1115823A1 (en) 2008-12-12
WO2006100567B1 (en) 2006-11-30
US20060217312A1 (en) 2006-09-28
US8206750B2 (en) 2012-06-26
AU2006226045A1 (en) 2006-09-28
EP1871341B1 (en) 2012-02-29
CN101170994A (zh) 2008-04-30
EP2327396A2 (en) 2011-06-01
SI2289490T1 (sl) 2014-11-28

Similar Documents

Publication Publication Date Title
IL186169A0 (en) Charged lipoprotein complexes and their uses
PH12014502397A1 (en) Pesticidal compositions and processes related thereto
ZA200706010B (en) 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-hetero-ayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
CR9672A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
SI1888595T1 (sl) Spojine spiro oksindola in uporaba le teh kot terapevtskih agensov
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
PL387008A1 (pl) Sposób oczyszczania triorganofosforynów przez obróbkę dodatkiem zasadowym
MX2015008072A (es) Composiciones plaguicidas y los procedimientos relacionados con las mismas.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
TW200505790A (en) Surface- modified precipitated silicas
GB0820833D0 (en) The neg-g-air cord 01
GB0423927D0 (en) The treatment of IBD
UA68150U (en) Valiusha', decorative candle
AU308079S (en) Fencing panel
AU303867S (en) Left boot
AU315791S (en) Caravan
AU4839P (en) Co-op 33 Malus domestica
AU5423P (en) Co-op 39 Malus domestica
HK1157335A (en) Therapeutic agents 414
HK1149712A (en) Combination therapy 238
AU303865S (en) Left boot
UA84625C2 (en) Ethylhydroxyphosphonylmethyltetrapropoxycalix[4]arene as amino acids complexing agent
AU316107S (en) Blower pulleys